Marinus Pharmaceuticals Inc. (MRNS)’s Financial Results Comparing With Global Cord Blood Corporation (NYSE:CO)

Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) and Global Cord Blood Corporation (NYSE:CO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Marinus Pharmaceuticals Inc. N/A 0.00 43.21M -0.99 0.00
Global Cord Blood Corporation N/A 0.00 N/A 0.27 24.01

Table 1 highlights Marinus Pharmaceuticals Inc. and Global Cord Blood Corporation’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Marinus Pharmaceuticals Inc. and Global Cord Blood Corporation.

Net Margins Return on Equity Return on Assets
Marinus Pharmaceuticals Inc. 0.00% -83.8% -74%
Global Cord Blood Corporation 0.00% 7.2% 3.8%

Risk & Volatility

A 3.27 beta indicates that Marinus Pharmaceuticals Inc. is 227.00% more volatile compared to Standard & Poor’s 500. In other hand, Global Cord Blood Corporation has beta of 0.38 which is 62.00% less volatile than Standard & Poor’s 500.

Liquidity

Marinus Pharmaceuticals Inc.’s Current Ratio is 9.4 while its Quick Ratio is 9.4. On the competitive side is, Global Cord Blood Corporation which has a 9.7 Current Ratio and a 9.6 Quick Ratio. Global Cord Blood Corporation is better positioned to pay off short and long-term obligations compared to Marinus Pharmaceuticals Inc.

Dividends

Global Cord Blood Corporation has an annual dividend pay of $0.08 per share while its annual dividend yield is 1.18%. Marinus Pharmaceuticals Inc. does not offer a dividend.

Analyst Ratings

In next table is shown Marinus Pharmaceuticals Inc. and Global Cord Blood Corporation’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Marinus Pharmaceuticals Inc. 0 1 4 2.80
Global Cord Blood Corporation 0 0 0 0.00

Marinus Pharmaceuticals Inc. has an average target price of $15.42, and a 259.44% upside potential.

Institutional & Insider Ownership

The shares of both Marinus Pharmaceuticals Inc. and Global Cord Blood Corporation are owned by institutional investors at 72.4% and 18.2% respectively. Marinus Pharmaceuticals Inc.’s share held by insiders are 0.6%. Competitively, insiders own roughly 49.6% of Global Cord Blood Corporation’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Marinus Pharmaceuticals Inc. 4.36% 15.14% 39.24% -9.79% 0% 66.9%
Global Cord Blood Corporation -1.35% -7.19% -2.08% -2.37% -31.39% 2.02%

For the past year Marinus Pharmaceuticals Inc. was more bullish than Global Cord Blood Corporation.

Summary

Global Cord Blood Corporation beats Marinus Pharmaceuticals Inc. on 7 of the 9 factors.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.